The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401)

被引：0
|
作者：
Small, Eric Jay
Halabi, Susan
Carducci, Michael Anthony
Ryan, Charles J.
George, Daniel J.
Mahoney, John Francis
Stadler, Walter Michael
Morris, Michael J.
Kantoff, Philip
Monk, J. P.
Kelly, William Kevin
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Duke Univ, Sch Med, Durham, NC USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[6] Duke Canc Inst, Durham, NC USA
[7] Carolinas Hematol Oncol Associates, Charlotte, NC USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
[11] Ohio State Univ, CALGB, Columbus, OH 43210 USA
[12] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4667
引用
收藏
页数：1
相关论文
共 50 条
  • [41] No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer
    Hideaki Miyake
    Takayuki Sugiyama
    Ryota Aki
    Yuto Matsushita
    Keita Tamura
    Daisuke Motoyama
    Toshiki Ito
    Atsushi Otsuka
    Medical Oncology, 2017, 34
  • [42] No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer
    Miyake, Hideaki
    Sugiyama, Takayuki
    Aki, Ryota
    Matsushita, Yuto
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Otsuka, Atsushi
    MEDICAL ONCOLOGY, 2017, 34 (08)
  • [43] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
  • [44] Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium
    Harzstark, A. L.
    Beer, T. M.
    Weinberg, V. K.
    Higano, C. S.
    Nordquist, L. T.
    Rosenberg, J. E.
    Alumkal, J. J.
    Yu, E. Y.
    Mi, J.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [45] Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE)
    Tannock, Ian
    Fizazi, Karim
    Ivanov, Sergei
    Karlsson, Camilla Thellenberg
    Flechon, Aude
    Skoneczna, Iwona Anna
    Orlandi, Francisco Jorquera
    Gravis, Gwenaelle
    Matveev, Vsevolod B.
    Bavbek, Sevil E.
    Gil, Thierry
    Viana, Luciano S.
    Aren, Osvaldo Rudy
    Karyakin, Oleg
    Elliott, Tony
    Birtle, Alison J.
    Magherini, Emmanuelle
    Hatteville, Laurence
    Tombal, Bertrand
    Rosenthal, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [46] A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Powles, Thomas
    Fizazi, Karim
    Gillessen, Silke
    Drake, Charles G.
    Rathkopf, Dana E.
    Narayanan, Sujata
    Green, Marjorie C.
    Mecke, Almut
    Schiff, Christina
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) refractory to docetaxel (D).
    Peer, Avivit
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Boursi, Ben
    Leibowitz-Amit, Raya
    Berger, Raanan
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Pili, Roberto
    Hammers, Hans J.
    Sinibaldi, Victoria J.
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer
    Robin, Gabrielle
    Basappa, Naveen S.
    North, Scott
    Ghosh, Sunita
    Kolinsky, Michael
    CURRENT ONCOLOGY, 2024, 31 (09) : 5080 - 5087
  • [49] Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Marttila, Timo
    Jekunen, Antti
    Hervonen, Petteri
    Klintrup, Katariina
    Kataja, Vesa
    Utriainen, Tapio
    Luukkaa, Marjaana
    Leskinen, Markku
    Pulkkanen, Kalevi
    Kautio, Anna-Liisa
    Huttunen, Teppo
    ANTICANCER RESEARCH, 2020, 40 (12) : 6915 - 6921
  • [50] Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.
    Hussain, M.
    Smith, M. R.
    Sweeney, C.
    Corn, P. G.
    Elfiky, A.
    Gordon, M. S.
    Haas, N. B.
    Harzstark, A. L.
    Kurzrock, R.
    Lara, P.
    Lin, C.
    Sella, A.
    Small, E. J.
    Spira, A. I.
    Vaishampayan, U. N.
    Vogelzang, N. J.
    Scheffold, C.
    Ballinger, M. D.
    Schimmoller, F.
    Smith, D. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345